Qsymia is the second most-prescribed oral obesity medication in the United States, and it's meaningfully cheaper than the GLP-1 medications that have dominated weight loss conversations since 2021. For patients who can't afford Ozempic or Wegovy, or who aren't candidates for injectables, Qsymia is a real option worth understanding.
But it comes with trade-offs that GLP-1 medications don't: it's a controlled substance, it requires a federal REMS program, it can't be prescribed through most telehealth platforms, and its pregnancy contraindication is among the most serious in outpatient medicine. This guide lays out the clinical and practical comparison so you can have an informed conversation with your provider.
Quick Comparison
| Qsymia | Semaglutide (Wegovy/Ozempic) | Tirzepatide (Zepbound) | |
|---|---|---|---|
| Active ingredients | Phentermine + topiramate ER | Semaglutide | Tirzepatide |
| Mechanism | Appetite suppressant + anticonvulsant | GLP-1 receptor agonist | GIP + GLP-1 receptor agonist |
| FDA-approved for obesity | Yes (2012) | Yes (Wegovy, 2021) | Yes (Zepbound, 2023) |
| Route of administration | Oral (once daily) | Injection (once weekly) | Injection (once weekly) |
| Avg. weight loss (max dose) | ~9–11% body weight | ~15% body weight | ~20%+ body weight |
| Controlled substance | Schedule IV | No | No |
| REMS program required | Yes | No | No |
| Telehealth availability | Very limited | Widely available | Available through select providers |
| Brand retail price | ~$100–$200/month | ~$1,300–$1,500/month (Wegovy) | ~$1,000–$1,200/month (Zepbound) |
| Compounded alternative | No | Yes ($99–$450/month) | Limited availability |
What Qsymia Is
Qsymia is an FDA-approved combination medication for chronic weight management, containing two active ingredients:
Phentermine — a sympathomimetic amine related to amphetamine, classified as a Schedule IV controlled substance. It suppresses appetite by stimulating norepinephrine release in the brain. Phentermine alone has been FDA-approved since 1959 for short-term weight loss; in Qsymia, the extended-release formulation of topiramate allows phentermine to be used long-term.
Topiramate ER — an anticonvulsant drug also approved for migraine prevention. Its weight loss mechanism is not fully understood but appears to involve GABA receptor modulation, appetite suppression, and reduced reward response to food. Topiramate is highly teratogenic — it causes fetal harm, specifically orofacial clefts — which is the basis for the Qsymia REMS program.
Qsymia comes in four doses:
| Dose | Phentermine | Topiramate ER |
|---|---|---|
| Starting | 3.75 mg | 23 mg |
| Recommended | 7.5 mg | 46 mg |
| Escalation | 11.25 mg | 69 mg |
| Highest | 15 mg | 92 mg |
The standard approach is to start at 3.75mg/23mg for 14 days, then increase to 7.5mg/46mg. If 3% weight loss isn't achieved by week 12, the dose may be escalated toward the maximum.
Who Qsymia Is Approved For
FDA-approved for adults with:
- BMI ≥ 30 kg/m² (obesity), or
- BMI ≥ 27 kg/m² with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia)
Alongside a reduced-calorie diet and increased physical activity.
Contraindications
- Pregnancy (Category X for topiramate — major teratogen; causes orofacial clefts)
- Glaucoma
- Hyperthyroidism
- History of MAO inhibitor use within 14 days
- Hypersensitivity to sympathomimetic amines
Women of childbearing potential must use effective contraception and receive a negative pregnancy test before starting and monthly thereafter.
Efficacy: Weight Loss Data
Qsymia Clinical Trials
Two pivotal trials established Qsymia's efficacy:
EQUIP trial (1,267 patients, 56 weeks):
- Qsymia 15mg/92mg: −10.9% average weight loss
- Qsymia 3.75mg/23mg: −5.1% average weight loss
- Placebo: −1.6% average weight loss
CONQUER trial (2,487 patients with comorbidities, 56 weeks):
- Qsymia 15mg/92mg: −9.8% average weight loss
- Qsymia 7.5mg/46mg: −7.8% average weight loss
- Placebo: −1.2% average weight loss
At the highest dose, approximately half of patients achieved ≥10% weight loss and about a third achieved ≥15%.
GLP-1 Clinical Trials
STEP 1 trial (semaglutide 2.4mg, 1,961 patients, 68 weeks):
- Semaglutide 2.4mg (Wegovy dose): −14.9% average weight loss
- Placebo: −2.4% average weight loss
- 69.1% of patients achieved ≥10% weight loss; 50.5% achieved ≥15%
SURMOUNT-1 trial (tirzepatide 15mg, 2,519 patients, 72 weeks):
- Tirzepatide 15mg (Zepbound): −20.9% average weight loss
- 57% of patients achieved ≥20% weight loss
No head-to-head trials between Qsymia and GLP-1 medications exist. Indirect comparison is imperfect, but the magnitude of weight loss consistently favors GLP-1 medications — particularly semaglutide and tirzepatide — over Qsymia.
For patients comparing options for maximal weight loss: GLP-1 medications, especially tirzepatide, have the strongest efficacy data currently available. See our phentermine vs GLP-1 comparison for a broader look at how phentermine-based approaches stack up against the GLP-1 class.
Side Effects
Qsymia Side Effects
Phentermine-related:
- Increased heart rate — phentermine is a stimulant and raises resting heart rate
- Elevated blood pressure
- Insomnia — particularly if taken late in the day
- Dry mouth
- Constipation
- Anxiety or irritability — stimulant effect
Topiramate-related:
- Cognitive effects — "word-finding" difficulty, memory issues, attention problems (colloquially called "topamax brain fog")
- Paresthesia — tingling in hands and feet
- Metabolic acidosis — particularly at higher doses or in patients with kidney disease
- Increased risk of kidney stones
- Taste changes
Serious:
- Teratogenicity — fetal harm if taken during pregnancy (major concern for women of childbearing potential)
- Increased suicidal ideation risk — shared class effect with topiramate and other anticonvulsants
- Cardiovascular effects — not recommended in patients with coronary artery disease or recent cardiac events
GLP-1 Side Effects
- Nausea — most common, especially during dose escalation (typically improves in 4–8 weeks)
- Vomiting and diarrhea
- Constipation
- Injection site reactions (for injectable GLP-1s)
- Decreased appetite (mechanism, also listed as side effect)
Serious (rare):
- Pancreatitis
- Gallbladder disease
- Thyroid C-cell tumors (contraindicated in MTC/MEN2 history)
The side effect profiles are fundamentally different because the mechanisms are completely different. Patients who don't tolerate GLP-1 nausea may tolerate Qsymia better — and vice versa (patients who can't tolerate stimulant effects or topiramate cognitive effects may do better on a GLP-1).
Cost Comparison
Without Insurance
| Medication | Monthly Cost (Approximate) |
|---|---|
| Qsymia (7.5mg/46mg) | ~$100–$150 |
| Qsymia (15mg/92mg) | ~$150–$200 |
| Wegovy (brand semaglutide 2.4mg) | ~$1,300–$1,500 |
| Zepbound (brand tirzepatide) | ~$1,000–$1,200 |
| Compounded semaglutide (telehealth) | ~$99–$450 |
Qsymia is meaningfully cheaper than brand-name GLP-1 medications. However, compounded semaglutide available through telehealth providers has brought semaglutide pricing into the same range as Qsymia. For patients without insurance or with poor GLP-1 coverage, comparing Qsymia to compounded semaglutide — not to brand-name Wegovy — is the most practical cost analysis.
With Insurance
Qsymia's insurance coverage is variable. Some plans cover it under obesity/weight management benefits; others don't. Many employer plans that exclude GLP-1s for weight loss also exclude Qsymia.
When coverage exists, Qsymia copays are typically $25–$75/month. Novo Nordisk and Eli Lilly offer manufacturer savings cards for brand-name GLP-1s. Qsymia also has a manufacturer savings program (Vivus) for commercially insured patients.
Access: Telehealth, Prescribing, and REMS
Qsymia's Access Challenges
Qsymia cannot be prescribed through most telehealth platforms due to:
- Controlled substance restrictions — phentermine is Schedule IV, and prescribing controlled substances via telehealth requires specific DEA authorization and, depending on state rules, may require in-person evaluation
- REMS program — prescribers must be enrolled in the Qsymia REMS and follow specific protocols: negative pregnancy test before prescribing, monthly pregnancy tests for women of childbearing potential, and specific dispensing through certified pharmacies
- State-level restrictions — some states have additional limitations on controlled substance telehealth prescribing
In practice, most patients access Qsymia through in-person visits with primary care physicians, obesity medicine specialists, or endocrinologists.
GLP-1 Access Through Telehealth
GLP-1 medications are not controlled substances and do not require a REMS program. Compounded semaglutide has been the most widely available option:
- 17+ telehealth providers in the TeleHealthAlly database offer semaglutide (compounded, brand, or both)
- Most operate fully asynchronously or with video consultation
- Many ship to all 50 states
- No in-person visit required
For patients who prefer telehealth access, GLP-1 medications are the practical option. Use our provider comparison tool to find options in your state and at your price point.
Who Should Consider Each Option
Qsymia May Be the Better Fit If:
- You have had a negative experience with GLP-1 nausea and can't tolerate injectable side effects
- You strongly prefer an oral medication and find injections a barrier
- You have good insurance coverage for Qsymia and poor coverage for GLP-1s
- You previously responded well to phentermine and want a more structured, longer-term version
- You are not pregnant, not planning pregnancy, and using reliable contraception
- You need lower out-of-pocket cost and compounded semaglutide isn't accessible in your area
Qsymia is not appropriate if:
- You are pregnant, planning pregnancy, or cannot use reliable contraception
- You have glaucoma, hyperthyroidism, or cardiovascular disease
- You have a history of substance use disorder (controlled substance concern)
- You experience significant cognitive side effects from other medications
GLP-1 Medications Are the Better Fit If:
- Maximum weight loss efficacy is a priority (GLP-1s, especially tirzepatide, have the stronger data)
- You have type 2 diabetes (GLP-1s have dual indication)
- Cardiovascular risk reduction is a clinical goal (GLP-1s have established CV outcome trials)
- Telehealth access is important to you
- You want to avoid controlled substances
- You're planning pregnancy now or in the future (GLP-1s stop 2 months before; Qsymia is contraindicated entirely)
A Note on Combining Approaches
Phentermine and GLP-1 medications are sometimes prescribed together in clinical practice — a combination not FDA-approved but used off-label by some obesity medicine specialists, particularly for patients who have plateaued on a GLP-1 alone. This is outside the scope of most telehealth programs and requires careful monitoring. Do not combine these medications without explicit prescriber guidance.
Frequently Asked Questions
Which produces more weight loss — Qsymia or Ozempic?
Ozempic's active ingredient semaglutide, at the obesity-indicated dose (2.4mg via Wegovy), produces more weight loss than Qsymia in clinical trials: approximately 15% body weight reduction for semaglutide versus 9–11% for Qsymia at maximum dose. No direct head-to-head trial exists, but indirect comparison consistently favors GLP-1 medications. Tirzepatide (Mounjaro/Zepbound) produces even greater weight loss (~20%) than semaglutide.
Can Qsymia be prescribed through telehealth?
Qsymia is very difficult to access through telehealth due to two barriers: phentermine is a Schedule IV controlled substance with telehealth prescribing restrictions, and Qsymia requires enrollment in a federal REMS program that mandates pregnancy testing and specific monitoring. Most patients access Qsymia through traditional in-person clinical visits.
Is Qsymia cheaper than GLP-1 medications?
Qsymia ($100–$200/month) is significantly cheaper than brand-name Wegovy ($1,300–$1,500/month) or Zepbound (~$1,000–$1,200/month). However, compounded semaglutide through telehealth providers is available for $99–$450/month — comparable to Qsymia's price while offering greater weight loss efficacy. When comparing costs, including compounded semaglutide in the analysis is essential.
Who should not take Qsymia?
Qsymia is contraindicated in people who are pregnant or planning pregnancy (topiramate causes serious fetal birth defects), women who cannot use reliable contraception, people with glaucoma, hyperthyroidism, recent or planned cardiovascular events, or hypersensitivity to sympathomimetic amines. It should also be used with caution in patients with a history of substance use disorder given phentermine's Schedule IV classification.